(AIM: SAR)

29 November 2016

SAREUM HOLDINGS PLC

(“Sareum” or the “Company”)

Sareum to Present TYK2 Cancer Research Programme
at the 2016 AACR-NCI-EORTC International Conference

Sareum Holdings plc, the specialist cancer drug discovery and development business, is pleased to announce that it will present the latest results from its TYK2 cancer research programme at the American Association for Cancer Research (AACR) National Cancer Institute (NCI) European Organisation for Research and Treatment of Cancer (EORTC) International Conference, to be held between 29 November and 2 December 2016 in Munich, Germany.

On Tuesday 29 November, Sareum’s CSO, Dr John Reader, will present a poster* that describes the discovery of the TKY2 anti-cancer programme lead compounds and their effectiveness in a disease model of T-Cell Acute Lymphoblastic Leukaemia (T-ALL).

The Company announced, on 24 October, that a feasibility study into the potential for its TYK2 inhibitors to treat T-ALL, part funded by the Innovate UK BioMedical Catalyst, had concluded successfully. The study culminated in a T-ALL disease model study in which Sareum’s compounds, dosed orally, were well tolerated, presented good exposure to plasma and tumour tissue and showed a dose-dependent effect on a biomarker of TYK2 inhibition and tumour reduction of up to 80%.  

* Session “Molecular Targeted Agents I”
“Characterisation of TYK2 Inhibitors as Potential T-cell Acute Lymphoblastic Leukaemia Therapeutics.” Abstract #48, Poster Board #19

Sareum’s CEO, Dr Tim Mitchell, commented: “Sareum’s progress with TYK2 inhibitors as anti-cancer agents adds significant value to our success with these compounds in autoimmune disease models. We are delighted to be presenting these results at this important cancer conference, which we expect representatives from most of our potential customer companies to attend. ”

For further information:

Sareum Holdings plc

 

Tim Mitchell

01223 497 700

WH Ireland Limited (Nominated Adviser and Co-Broker)

Chris Fielding / Nick Prowting

020 7220 1666

Hybridan LLP (Co-Broker)

 

Claire Noyce / William Lynne

020 3764 2341/2342

The Communications Portfolio (Sareum Media enquiries)

 

Ariane Comstive
Ariane.comstive@communications-portfolio.co.uk 

07785 922 354

Notes for editors:

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum operates an outsourced research model, working with international collaborators and a world-wide network of research providers. Its most advanced programme (Chk1) commenced clinical trials in May 2016 and was licensed to NASDAQ-listed ProNAi Therapeutics in September 2016.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease research programmes, which are in the IND-enabling preclinical and lead optimisation stages respectively. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk

T-Cell Acute Lymphoblastic Leukaemia (T-ALL) is a rare type of leukaemia that is more common in older children and teenagers. It affects a type of white blood cell called T-cells. It is aggressive and progresses quickly. Around 200 people are diagnosed with T-ALL in the UK every year. It usually occurs in late childhood or early adolescence and is significantly more common in boys than girls.

 

  • @Sareumplc Latest tweet

    RT @HybridanLLP: .@Sareumplc's (SAR) license partner provides Q2 operational update and outline of potential milestone payments on SRA737.… via @Sareumplc
    View more